Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations)
Journal: Russian Annals of Ophthalmology. 2022;138(3): 68‑72
Views: 1497
Downloaded: 28
To cite this article:
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.